Browsing by Author Ratjen, F.
Showing results 1 to 8 of 8
| Publication Year | Title | Author(s) |
|---|---|---|
| 2018 | Effect of lumacaftor/ivacaftor on ct scores: Exploratory imaging substudy | Wainwright, Claire ; Hug, C.; Marigowda, G.; Waltz, D.; Goldin, J.; Ratjen, F.; Wang, L.; Brody, A.; Nagle, S. |
| 2022 | Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3B, Randomized, Placebo-Controlled Study | Brugha, R.; Gartner, S.; Legg, J.; Moeller, A.; Mondejar-Lopez, P.; Prais, D.; Pressler, T.; Ratjen, F.; Reix, P.; Robinson, P. D.; Selvadurai, H.; Stehling, F.; Ahluwalia, N.; Arteaga-Solis, E.; Bruinsma, B. G.; Jennings, M.; Moskowitz, S. M.; Noel, S.; Tian, S.; Weinstock, T. G.; Wu, P.; Wainwright, Claire ; Davies, J. C.; Mall, M. A. |
| 2021 | Elexacaftor/tezacaftor/ivacaftor in children aged 6 and older with cystic fibrosis and at least 1 F508del allele: Interim results from a Phase 3 open-label extension study | Noel, S.; Ahluwalia, N.; Chu, C.; Moskowitz, S.; Wainwright, C. ; Davies, J.; Weinstock, T.; Waltz, D.; Ratjen, F.; Escobar, H.; Gaffin, J.; McColley, S.; Roesch, E.; Ruiz, F. |
| 2018 | Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study | Ratjen, F.; Rubenstein, R.; Walker, S.; Black, P.; Montgomery, G.; McColley, S.; Hiatt, P.; Sawicki, G.; Rock, M.; Aurora, P.; Milla, C.; Maitra, A.; Ives, A.; Gaillard, E.; McNalley, P.; Selvadurai, H.; Robinson, P.; Rosenfeld, M.; Wainwright, C. E. ; Higgins, M.; Wang, L. T.; McKee, C.; Campbell, D.; Tian, S.; Schneider, J.; Cunningham, S.; Davies, J. C.; Harris, W.; Mogayzel, P.; McCoy, K. |
| 2023 | Long-term safety and efficacy of elexacaftor-tezacaftor-ivacaftor in children aged 6 and older with cystic fibrosis and at least one F508del allele: 144-week results of an open-label extension study | Wainwright, C. ; McColley, S.; McNally, P.; Powers, M.; Ratjen, F.; Rayment, J.; Retsch-Bogart, G.; Roesch, E.; Ahluwalia, N.; Chu, C.; Menon, P.; Weinstock, T.; Davies, J. |
| 2015 | Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for phe508del CFTR | Munck, A.; Wainwright, Claire ; Elborn, J. S.; Ramsey, B. W.; Marigowda, G.; Huang, X.; Cipolli, M.; Colombo, C.; Davies, J. C.; De Boeck, K.; Flume, P. A.; Ratjen, F.; Boyle, M. P.; Waltz, D.; Rowe, S. M.; Konstan, M. W.; McColley, S. A.; McCoy, K.; McKone, E. F. |
| 2021 | Time to get serious about the detection and monitoring of early lung disease in cystic fibrosis | Robinson, P. D.; Stick, S.; Wainwright, Claire ; Bayfield, K. J.; Douglas, T. A.; Rosenow, T.; Davies, J. C.; Elborn, S. J.; Mall, M.; Paproki, A.; Ratjen, F.; Sly, P. D.; Smyth, A. R. |
| 2018 | Ultrashort echo time MRI can evaluate treatment effect of Lumacaftor/Ivacaftor | Nagle, S.; Johnson, K.; Wang, L.; Marigowda, G.; Waltz, D.; Goldin, J.; Ratjen, F.; Hug, C.; Wainwright, C. ; Woods, J.; Brody, A. |